drugset / Trial / NCT04099563

Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants

NCT04099563

Phase 1 Completed 13 enrolled Pfizer
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetics, safety and tolerability of PF-04965842 after single dose and once-daily multiple-doses in Chinese healthy participants.

Timeline

Start
2019-10-14
Primary completion
2019-11-09
Completion
2019-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Abrocitinib Small molecule 200 mg Oral

Indications

No indication recorded.